Capsule coated tablets, Tysabri 300 mg concentrate for solution for infusion, Vemlidy 25 mg film-coated tablets. clinical trials

Tenofovir Alafenamide Fumarate and Epstein-Barr virus activity in people with MS – The TAF-MS study

This study, called TAF-MS, is looking into how a medicine called Tenofovir Alafenamide Fumarate (TAF) affects the Epstein-Barr virus (EBV) in people with Multiple Sclerosis (MS). Researchers want to see if this treatment can help reduce EBV activity, which may be linked to MS.